drugset / Trial / NCT02104752

Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia

NCT02104752

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The investigators propose to test whether curcumin nanoparticles will improve behavioral measures and biomarkers of cognition and neuroplasticity in patients with schizophrenia who are already receiving a stable dose of antipsychotic.

Timeline

Start
2014-07
Primary completion
2016-05
Completion
2017-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Curcumin Small molecule 360 mg Oral

Indications